Tehran, Iran – September 13, 2024 — In a significant breakthrough for cell therapy and regenerative medicine, Taskin Bioregeneration Co. has announced that its cutting-edge product, DestroCell, has received initial approval from the Iranian FDA for treating Steroid-Resistant Graft-versus-Host Disease (SR-GvHD). This approval marks a major milestone in the fight against one of the most challenging complications faced by transplant patients.
DestroCell is a revolutionary placenta-derived stromal cell therapy with powerful immunomodulatory effects, targeting acute inflammatory diseases and autoimmune disorders. Developed to combat the severe challenges posed by SR-GvHD, the therapy has shown remarkable success in clinical trials across Europe, North America, and Iran.
Leading these groundbreaking studies, Dr. Sadeghi, Director of Research and Development at Taskin Bioregeneration, stated: “Our clinical trials demonstrated DestroCell’s extraordinary efficacy and safety. Every patient treated with DestroCell responded positively, achieving either partial or complete remission within just four weeks. These results are particularly exciting, given the limited therapeutic options available for this critical condition.”
DestroCell works by modulating the immune system, specifically inhibiting the activity of invading lymphocytes, which are responsible for the severe tissue damage seen in SR-GvHD. Administered intravenously, the first therapeutic effects are seen within 24 hours post-injection, offering both localized and systemic relief to patients in critical need.
A New Era in Treating Acute Inflammatory Diseases
In addition to its use in SR-GvHD, DestroCell is currently under investigation for other acute inflammatory conditions, including Acute Respiratory Distress Syndrome (ARDS) and autoimmune disorders. This expansion underscores Taskin’s mission to bring innovative treatments to market that address significant unmet medical needs.
Taskin Bioregeneration CEO, Dr. Naser Aghdami, expressed his excitement: “DestroCell is a game-changer for patients battling life-threatening inflammatory diseases. Our goal is to push the boundaries of cell therapy and regenerative medicine, offering patients cutting-edge solutions that save lives.”
The Challenge of GVHD
Graft-versus-Host Disease (GVHD) is a serious complication following allogeneic hematopoietic cell transplantation (aHCT), where the donor’s immune cells attack the recipient’s tissues. When standard steroid treatments fail, the condition becomes steroid-resistant GVHD (SR-GvHD), leaving patients with very limited treatment options and alarmingly high mortality rates. DestroCell provides a beacon of hope for these patients, offering a new approach to managing this devastating disease.
About Taskin Bioregeneration Co.
Taskin Bioregeneration, based in Tehran, Iran, is a leader in the research and development of advanced cell therapies. The company is committed to creating innovative treatments that harness the body’s own regenerative capabilities to fight diseases. With DestroCell, Taskin is at the forefront of a new era in cell therapy, aiming to revolutionize the treatment landscape for acute inflammatory and autoimmune diseases.
For more information, visit Taskin Bioregeneration Co.